Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
Executive Summary
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
You may also be interested in...
Boston Scientific Adds More Non-Vascular Stents To MedSurg Business With MI Tech Acquisition
Boston Scientific will pay about $230m for 64% of Korea-based MI Tech, which developed the Hanarostent line of conformable, self-expanding metal stents for endoscopic and urologic applications.
NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.
Boston Scientific Puts Charge In Neuromodulation Business By Acquiring Relievant
Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.